all report title image
  • Published On : Aug 2020
  • Code : CMI1271
  • Industry : Pharmaceutical
  • Pages : 188
  • Formats :

Immuno-oncology drugs target the body’s natural defenses, the immune system, to fight cancer. Oncology drugs are therapeutics used to treat cancer, a group of diseases caused by uncontrolled growth and division of abnormal cells. Immuno-oncology drugs include a range of different types of medications, such as chemotherapy agents, targeted therapies, immunotherapies, and hormone therapies. There are also different types of drugs available to help treat the side effects from oncology drugs. Immunotherapy is treatment that uses a certain part of a person’s immune system to fight diseases which is done by stimulating one’s own immune system to work harder to attack cancer cells or by giving immune system components, such as man-made immune system proteins. Immunotherapy includes treatments that work in different ways. Some boost the body’s immune system in a very general way and others help train the immune system to attack cancer cells specifically.

The global Immuno-oncology drugs market is estimated to be valued at US$ 17,394.2 million in 2022 and is expected to exhibit a CAGR of 16.8% during the forecast period (2022-2030).

Figure 1. Global Immuno-oncology Drugs Market Share (%), by Disease Type, 2022

Immuno-oncology Drugs  | Coherent Market Insights

Global Immuno-oncology Drugs Market - Drivers

Increasing adoption of organic strategies such as funding by key market players is expected to drive the global Immuno-oncology drugs market growth over the forecast period. For instance, in July 2020, Agenus Inc., a biotechnology company, announced the closing of a US$ 20 million equity investment, at US$ 4.03 per share, by Betta Pharmaceuticals Co., Ltd., bringing the total received to US$ 35M. This funding will enable Betta to receive exclusive rights for the development and commercialization of balstilimab and zalifrelimab, as both monotherapies and combination therapies, excluding intravesical delivery, in greater China.

CMI table icon

Immuno-oncology Drugs Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 17,394.2 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 16.8% 2030 Value Projection: US$ 60,186.2 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Treatment Type: Immune Checkpoint Inhibitors ( PD-1, PD-L1, CTLA-4), Immune System Modulators, Cancer Vaccines, Oncolytic Virus, Others
  • By Disease Type: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Prostate Cancer, Bladder Cancer, Others (Breast Cancer, Thyroid Cancer, etc.)
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

AbbVie Inc., AstraZeneca, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals LLC., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Ferring B.V., Enzo Biochem Inc., Celldex Therapeutics, Atara Biotherapeutics, Inc., Apexigen, BioNTech SE, Blueprint Medicines Corporation, Regeneron Pharmaceuticals Inc., CytomX Therapeutics, Inc., Agenus Inc., Betta Pharmaceuticals Co., Ltd., CStone Pharmaceuticals, Amgen Inc., MediMergent, LLC, Gilead Sciences, Inc., and ONKO-INNATE

Growth Drivers:
  • Factors such as increasing adoption of inorganic strategies such as product approval and funding by key market players 
Restraints & Challenges:
  • Increasing number of product recalls by regulatory authorities such as the U.S. Food and Drug Administration

Figure 2. Global Immuno-oncology Drugs Market Value (US$ Million), by Region, 2022

Immuno-oncology Drugs  | Coherent Market Insights

Global Immuno-oncology Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a negative impact on the global Immuno-oncology drugs market. For instance, in October 2020, according to the data published in Nature Cancer journal, cancer patients are at higher risk of COVID-19 infections which is described by the immune responses that confer adverse reactions to this disease and indicate which antineoplastic therapies may either increase COVID-19 vulnerability or have a dual therapeutic effect on cancer. As COVID -19 is severe respiratory infection and linked to an inflammatory burst and lymphopenia, which may aggravate cancer prognosis. Hence, the management of oncology patients is the major challenge during COVID-19.

Global Immuno-oncology Drugs Market: Key Developments

Increasing adoption of inorganic strategies such as product approval by key market players is expected to drive global Immuno-oncology drugs market. For instance, in July 2022, CStone Pharmaceuticals, a bio-pharmaceutical company, announced the new drug application for GAVRETO (pralsetinib) has been approved in Hong Kong, China for the treatment of adult patients with rearranged during transfection fusion-positive metastatic non-small cell lung cancer.

Global Immuno-oncology Drugs Market: Restraint

Increasing number of product recalls by regulatory authorities such as the U.S. Food and Drug Administration is expected to hinder the market growth. For instance, in May 2022, the U.S. Food and Drug Administration recalled 2 lots of Mvasi (bevacizumab-awwb) injection due to defective containers, which was manufactured by Amgen Inc., a Biotechnology company. MVASI is indicated for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer.

Global Immuno-oncology Drugs Market - Key Players

Major players operating in the global immuno-oncology drugs market include AbbVie Inc., AstraZeneca, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals LLC., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Ferring B.V., Enzo Biochem Inc., Celldex Therapeutics, Atara Biotherapeutics, Inc., Apexigen, BioNTech SE, Blueprint Medicines Corporation, Regeneron Pharmaceuticals Inc., CytomX Therapeutics, Inc., Agenus Inc., Betta Pharmaceuticals Co., Ltd., CStone Pharmaceuticals, Amgen Inc., MediMergent, LLC, Gilead Sciences, Inc., and ONKO-INNATE

Immuno-oncology is the study and development of treatments that take advantage of the body’s immune system to fight cancer. As immune system is a complex network of organs, cells and molecules that protect the body from foreign substances that cause infection. In addition to finding and destroying foreign substances, the immune system can also locate and attack abnormal cells. Immuno-oncology uses novel immunotherapies that boost the immune system of patients. These therapies target the immune system of the body instead of the tumors and enable the immune system to recognize and target cancer cells. Immuno-oncology does not affect the functioning of healthy cells as opposed to conventional therapies such as chemotherapy and radiation therapy. Long term response can be generated with the help of these therapies as they provide long-lasting memory to the immune system. Immune system adapts to the cancer over time and provides long term response to the cancer. Immuno-Oncology therapy work against a wide variety of cancer, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others.

 Market Dynamics

Increasing number of inorganic strategies such as product approval by the key market players is expected to drive the global immuno-oncology drugs market over the forecast period. For instance, in December 2020, Blueprint Medicines Corporation, a biotech company, announced that they had received an approval from the U.S. Food and Drugs Administration for GAVRETO (pralsetinib) for the treatment of patients with advanced or metastatic RET-mutant and RET fusion-positive thyroid cancer. GAVRETO is a once-daily oral precision therapy designed to potently and selectively target RET alterations that drive multiple tumor types.

Key features of the study:

  • This report provides an in-depth analysis of the global immuno-oncology drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global immuno-oncology drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include AbbVie Inc., AstraZeneca, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals LLC., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Ferring B.V., Enzo Biochem Inc., Celldex Therapeutics, Atara Biotherapeutics, Inc., Apexigen, BioNTech SE, Blueprint Medicines Corporation, Regeneron Pharmaceuticals Inc., CytomX Therapeutics, Inc., Agenus Inc., Betta Pharmaceuticals Co., Ltd., CStone Pharmaceuticals, Amgen Inc., MediMergent, LLC, Gilead Sciences, Inc., and ONKO-INNATE
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global Immuno-oncology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immuno-oncology drugs market

Detailed Segmentation:

  • Global Immuno-oncology Drugs Market, By Treatment Type:
    • Immune Checkpoint Inhibitors
      • PD-1
      • PD-L1
      • CTLA-4
    • Immune System Modulators
    • Cancer Vaccines
    • Oncolytic Virus
    • Others
  • Global Immuno-oncology Drugs Market, By Disease Type:
    • Melanoma
    • Lung Cancer
    • Blood Cancer
    • Renal Cell Carcinoma
    • Prostate Cancer
    • Bladder Cancer
    • Others (Breast Cancer, Thyroid Cancer, etc.)
  • Global Immuno-oncology Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Immuno-oncology Drugs Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • AbbVie Inc.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Dendreon Pharmaceuticals LLC.
    • Hoffmann-La Roche Ltd.
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • Ferring B.V.
    • Enzo Biochem Inc.
    • Celldex Therapeutics
    • Atara Biotherapeutics, Inc.
    • Apexigen
    • BioNTech SE
    • Blueprint Medicines Corporation
    • Regeneron Pharmaceuticals Inc.
    • CytomX Therapeutics, Inc.
    • Agenus Inc.
    • Betta Pharmaceuticals Co., Ltd.
    • CStone Pharmaceuticals
    • Amgen Inc.
    • MediMergent, LLC,
    • Gilead Sciences, Inc.
    • ONKO-INNATE

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global immuno-oncology drugs market size is estimated to be valued at US$ 17,394.2 million in 2022 and is expected to exhibit a CAGR of 16.8% between 2022 and 2030.
Factors such as increasing adoption of inorganic strategies such as product approval and funding by key market players are expected to drive the market
Melanoma is the leading disease type segment in the market
Increasing number of product recalls by regulatory authorities such as the U.S. Food and Drug Administration are the major factors hampering growth of the market
Major players operating in the market include AbbVie Inc., AstraZeneca, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals LLC., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Ferring B.V., Enzo Biochem Inc., Celldex Therapeutics, Atara Biotherapeutics, Inc., Apexigen, BioNTech SE, Blueprint Medicines Corporation, Regeneron Pharmaceuticals Inc., CytomX Therapeutics, Inc., Agenus Inc., Betta Pharmaceuticals Co., Ltd., CStone Pharmaceuticals, Amgen Inc., MediMergent, LLC, Gilead Sciences, Inc., and ONKO-INNATE

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo